Christopher A Gabel

Title: Christopher A. Gabel: Innovator in Genetic Modification

Introduction

Christopher A. Gabel is a notable inventor based in Ledyard, Connecticut, who has made significant contributions to the field of genetic modification. With a focus on developing innovative solutions for medical applications, he holds 2 patents that showcase his expertise and dedication to advancing scientific knowledge.

Latest Patents

Gabel's latest patents include groundbreaking inventions such as "P2X7 receptor-deficient mice and uses thereof." This invention provides non-human, genetically-modified mammals and genetically modified animal cells that have a functionally disrupted P receptor gene. Additionally, it outlines methods for producing genetically modified mice in which one or both P R alleles have been functionally inactivated. Another significant patent is related to "Methods of screening compounds for their ability to inhibit the production of inflammatory cytokines." This invention identifies diarylsulfonylurea binding proteins (DBPs) as therapeutic targets for agents that suppress the release of inflammatory mediators such as interleukin IL-1 and IL-1β.

Career Highlights

Christopher A. Gabel is currently associated with Pfizer Corporation, a leading global pharmaceutical company. His work at Pfizer has allowed him to contribute to important research and development initiatives that aim to improve health outcomes through innovative therapies.

Collaborations

Gabel has collaborated with esteemed colleagues such as James F. Eggler and Beverly Koller, further enhancing the impact of his research through teamwork and shared expertise.

Conclusion

Christopher A. Gabel is a distinguished inventor whose work in genetic modification has the potential to transform medical research and treatment. His patents reflect a commitment to innovation and a desire to address critical health challenges.